Table 2.

ICER of LAIV Strategy Versus IIV Strategy (in 10³ USD per QALY)

ICER from healthcare perspective
	Effectiveness of IIV
		0%	15%	30%	45%	60%	75%	90%
Effectiveness of LAIV	0%	1670.2	IIV dominant	IIV dominant	IIV dominant	IIV dominant	IIV dominant	IIV dominant
	15%	45.4	1670.2	IIV dominant	IIV dominant	IIV dominant	IIV dominant	IIV dominant
	30%	12.2	47.9	1670.2	IIV dominant	IIV dominant	IIV dominant	IIV dominant
	45%	1.0	13.9	51.7	1670.2	IIV dominant	IIV dominant	IIV dominant
	60%	LAIV dominant	2.3	16.1	56.3	1670.2	IIV dominant	IIV dominant
	75%	LAIV dominant	LAIV dominant	3.9	18.8	62.3	1670.2	IIV dominant
	90%	LAIV dominant	LAIV dominant	LAIV dominant	6.1	22.4	70.0	1670.2
ICER from societal perspective
	Effectiveness of IIV
		0%	15%	30%	45%	60%	75%	90%
Effectiveness of LAIV	0%	1670.2	IIV dominant	IIV dominant	IIV dominant	IIV dominant	IIV dominant	IIV dominant
	15%	0.3	1670.2	IIV dominant	IIV dominant	IIV dominant	IIV dominant	IIV dominant
	30%	LAIV dominant	2.8	1670.2	IIV dominant	IIV dominant	IIV dominant	IIV dominant
	45%	LAIV dominant	LAIV dominant	6.7	1670.2	IIV dominant	IIV dominant	IIV dominant
	60%	LAIV dominant	LAIV dominant	LAIV dominant	11.4	1670.2	IIV dominant	IIV dominant
	75%	LAIV dominant	LAIV dominant	LAIV dominant	LAIV dominant	17.7	1670.2	IIV dominant
	90%	LAIV dominant	LAIV dominant	LAIV dominant	LAIV dominant	LAIV dominant	25.6	1670.2

ICER, incremental cost-effectiveness ratio; LAIV, live attenuated influenza vaccine; IIV, inactivated influenza vaccine; USD, United States dollars; QALY, quality-adjusted life years